|
The Drugs for Neglected Diseases Initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness (human African trypanosomiasis, HAT), Chagas disease,〔(Nature Outlook Chagas Disease supplement ). Nature Supplement, 2010 June, Vol. 465, No. 7301 suppl. ppS3-S22〕 malaria, paediatric HIV,〔(Pediatric HIV - A Neglected Disease ? ) by Lallemant M, Chang S, Cohen R, and Pécoul R. The New English Journal of Medicine. 2011 August. 365:581-583.〕 and specific helminth infections. Acting in the public interest and to respond to patients’ needs, DNDi bridges the existing R&D gaps in essential drugs for these diseases by leading drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners.〔(Future Medicinal Chemistry, "DNDi model of drug development for neglected diseases: current status andfuture challenges" ) - September 2011〕 The initiative’s primary objective is to deliver 11 to 13 new treatments by 2018 for these diseases and to establish a strong R&D portfolio. In doing so, DNDi is also working to use and strengthen existing capacities in disease-endemic countries, and advocate for the need to develop new treatments for the most neglected diseases. To date, DNDi has built the largest ever R&D portfolio for the kinetoplastid diseases (leishmaniasis, HAT, and Chagas) and has delivered 6 new treatments: 2 for malaria, 1 for HAT, 2 for visceral leishmaniasis, and 1 for Chagas disease. Led by its Executive Director Bernard Pécoul,〔(The Lancet, "Bernard Pécoul: championing the cause of neglected diseases" - August 2010 )〕 DNDi’s headquarters are in Geneva, Switzerland, with offices in Kenya, India, Brazil, Malaysia, Japan, the Democratic Republic of Congo, and an affiliate in the USA. == Origins == Despite major advances in drug development in recent decades, essential medicines to treat many diseases that affect the world’s poor are either too expensive, no longer produced, highly toxic, or ineffective. Well aware of these issues from its field experience in poor and remote areas, the humanitarian organization Médecins Sans Frontières committed its 1999 Nobel Peace Prize funds to develop an alternative model for the research and development (R&D) of new drugs for neglected diseases. As a result, in 2003, seven organizations from around the world joined forces to establish DNDi: • 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Drugs for Neglected Diseases Initiative」の詳細全文を読む スポンサード リンク
|